CURIS INC CRIS (NASDAQ)

$ 1.63
19:09
Change: +0.03 (+1.87%)
Volume: 147,800

Avg. Volume: 140715
P/E Ratio: 0
EPS (Annual): -0.07
Profit Margin:
Dividend & Yield(Annual): 0%
Shares Outstanding: 63,310
Institutional Shareholders: 50.87%
Last: 1.63
Change: +0.03 (+1.87%)
Prev. Close: 1.60
Open: 1.58
Day's Range: 1.52 - 1.63
52wk Range: 0.86 - 1.94
Market Value: 101,490
Beta: .41
12-month EPS Change: 0.00%
Total Return Last 12 Months: +58.25%
Total Return Last 3 Years: -270.87%
Total Return Last 5 Years: -56.65%
5-Year Revenue Growth Rate: 0.00%
5-Year Dividend Growth Rate: 0.00%
5-Year EPS Growth Rate: 0.00%


Headlines on CRIS
Alert me Subscribe

Partnerships drive big stock gains for small biotechs

(NEW YORK)As growth slows in shares of large-cap biotechs and economic woes weigh on the broader markets, investors can find dramatic growth opportunities in many small and midcap biotechs w...READ MORE
May 21, 2008 4:58PM
Keywords: CRIS, ADLR, GSK, PFE, DNA, ALKS, NKTR, VRTX, ARQL, MATK, CEPH, AMGN, REGN, SVNT, PDLI, GILD, BIIB, GENZ, LLY

Curis to receive $3 million payment from partner Genentech

(NEW YORK)Drug developer Curis Inc. said Monday it will receive a $3 million cash payment from partner Genentech Inc. as that company starts a midstage study on a potential colon cancer drug...READ MORE
May 05, 2008 2:21PM
Keywords: CRIS, DNA

Earnings Preview: Wyeth faces generic competition in 1Q

(NEW YORK)Drug maker Wyeth reports earnings for the first quarter on Tuesday. The following is a summary of key developments and analyst opinion related to the period.READ MORE
Apr 21, 2008 5:59AM
Keywords: TEVA, CRIS, WYE

Sector Wrap: Biotechnology

(NEW YORK)Analysts reduced sales estimates for Amgen's Aranesp anemia drug on Friday, after the Oncologic Drugs Advisory Committee recommended further restrictions on the drug's use in patie...READ MORE
Mar 14, 2008 2:07PM
Keywords: AMGN, JNJ, DNA, EXEL, CRIS, JPM, BSC

Wyeth Pulls Out of Curis Contract

(NEW YORK)Drug developer Curis Inc. said Monday its development partner Wyeth is ending a contract focused mainly on experimental treatments for heart conditions and strokes.READ MORE
Mar 10, 2008 11:09AM
Keywords: CRIS, WYE
RSS Page | Sign up for Google Alerts


Data Provided By Barchart.com
advertisement

Top Competitors

AMGEN +28.80 60.41
AMYLIN PHARMA I -56.90 21.11
GILEAD SCIENCES +15.20 47.85
BIOGEN IDEC INC -20.40 48.59
GENENTECH INC +33.90 96.64